Related Experiment Videos

Comparative nephrotoxicity of ribostamycin and gentamicin in rats evaluated by urinalysis

I Kitasato1, T Niizato, S Inouye

  • 1Research & Development, Meiji Seika Kaisha Ltd., Tokyo, Japan.

Drugs Under Experimental and Clinical Research
|January 1, 1989
PubMed

Insights

Ribostamycin exhibits lower nephrotoxicity than gentamicin in rats, showing minimal urinary changes and no significant kidney damage. This suggests ribostamycin is a safer alternative antibiotic.

Area of Science:

  • Pharmacology
  • Nephrology
  • Toxicology

Background:

  • Aminoglycoside antibiotics are crucial for treating bacterial infections.
  • Nephrotoxicity is a significant adverse effect limiting the use of certain aminoglycosides.
  • Comparing the renal safety profiles of different aminoglycosides is essential for clinical practice.

Purpose of the Study:

  • To compare the nephrotoxicity of ribostamycin and gentamicin in a rat model.
  • To evaluate the effects of these antibiotics on renal function using urinalysis and histopathology.
  • To assess the comparative renal accumulation and toxicity of ribostamycin against other aminoglycosides like kanamycin and dibekacin.

Main Methods:

  • Fischer rats were administered daily intramuscular doses of ribostamycin and gentamicin for 14 days.
  • Urinalysis was performed using 18 parameters to assess renal function.
  • Kidney histopathology was conducted to evaluate structural damage.
  • Renal accumulation of antibiotics was measured after a single dose.
  • Comparative toxicity was assessed against kanamycin and dibekacin.

Main Results:

  • Ribostamycin caused minimal changes in most urinary parameters compared to gentamicin, which induced significant alterations.
  • Histopathological examination revealed no significant kidney damage with ribostamycin, unlike gentamicin.
  • Ribostamycin showed a renal accumulation three times lower than gentamicin.
  • Ribostamycin demonstrated less nephrotoxicity than kanamycin and significantly less than dibekacin at equivalent doses.

Conclusions:

  • Ribostamycin exhibits a significantly better nephrotoxic profile than gentamicin in rats.
  • Urinalysis and histopathology confirm the lower renal toxicity of ribostamycin.
  • Ribostamycin represents a potentially safer aminoglycoside antibiotic option with reduced risk of kidney damage.

Related Concept Videos